Dr. Di Costanzo on the Effectiveness of Sorafenib in HCC

Giovan Giuseppe Di Costanzo, MD
Published: Wednesday, May 24, 2017



Giovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).

The scoring system was constructed to improve the therapeutic strategy for HCC, states Di Constanzo. For patients with advanced HCC the only approved treatment remains to be sorafenib, which is not effective in all patients.

There have been many studies aimed towards investigating ways to determine which patients will see positive results with sorafenib, states Di Costanzo.
 


Giovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).

The scoring system was constructed to improve the therapeutic strategy for HCC, states Di Constanzo. For patients with advanced HCC the only approved treatment remains to be sorafenib, which is not effective in all patients.

There have been many studies aimed towards investigating ways to determine which patients will see positive results with sorafenib, states Di Costanzo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x